Abstract: The present invention provides methods, systems, devices, panels, and software for determining values for two or more markers in order to characterize a subject's risk of developing cardiovascular disease or experiencing a complication thereof (e.g., within the ensuing one to three years), and for identifying subjects in need of preventative therapy (e.g., statins). In certain embodiments, the markers are selected from: hs-CRP, ACR, Lp-Pla2, MPO, fibrinogen, KIF6, and F2 isoprostanes.

Abstract: The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined.